Dr. Taylor Rose Carle, MD

Dr. Carle practices at Cedars-Sinai Medical Care Foundation in Beverly Hills, California.

Dr. Carle's NPI, 1548673692, was assigned on June 6, 2014. Dr. Carle graduated from Keck School of Medicine of USC in 2014. Dr. Carle holds California license A161283.

Dr. Carle's primary practice is Cedars-Sinai Medical Care Foundation, at 8501 Wilshire Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 385-3200.

Dr. Carle's primary practice is Cedars-Sinai Medical Care Foundation in Beverly Hills, California. Dr. Carle is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Carle to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carle practices, 3 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Carle's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Carle is board certified in otolaryngology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Carle's licenses on file in 2 states: California and Michigan.

CMS data shows 821 Medicare services from Dr. Carle across 7 procedure codes in 2024, for 428 Medicare patients. Medicare paid $69,998 for them. Every service was in an office.

CMS counts 428 Medicare patients who saw Dr. Carle in 2024. The largest group is 65 to 74, with 195 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.07, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Carle's median patient age at 53, with 59% women.

In 2024, Dr. Carle wrote 460 Medicare Part D claims for 189 patients. 98% of them were for generic drugs. CMS names the drug for 377 of them, across 6 drugs with 11 or more claims each, at $7,007 in total drug cost. In 2023, CMS named 277 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Carle for performance year 2024, reported as part of a group. Dr. Carle accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carle as offering telehealth.

Dmand AI links 5 papers to Dr. Carle, published from 2019 to 2023. Dr. Carle's most frequent co-authors are Scott Alan McLean, MD, PhD, Marilene Beth Wang, MD and Lauren Andrea Bohm, MD.

CMS Open Payments shows 76 general payments to Dr. Carle from 16 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 84% of the total. Medtronic, Inc. paid the most, $2,427.

Dr. Carle graduated from Keck School of Medicine of USC in 2014.

Dr. Carle is in network with 15 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.